TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Re-engagement in Evidence-based Quit Line Treatment for Low Income Smokers
Brief Summary: The purpose of this proposed study is to develop, refine and test the use of Interactive Voice Response (IVR) technology as a means of increasing re-engagement of low income smokers in telephone support for tobacco cessation (quit lines). If this strategy proves to be acceptable and feasible, it may offer a technological solution to increase access to and utilization of a widely available evidence-based form of behavioral treatment for low income smokers.

The primary aims of this research are to:

1. Develop an IVR system that delivers tailored audio messages to increase low income smokers' re-engagement in treatment offered by two state quit lines (Washington and Indiana). The investigators will develop: a) a menu of audio messages that can be delivered by an IVR system; b) an IVR algorithm (i.e., a set of decision rules) to make proactive automated calls to deliver brief, tailored messages for re-engaging low income smokers who previously used the quit line.
2. Evaluate the feasibility and efficacy of an IVR system as a tool to re-engage low income smokers into quit line treatment measured by number of IVR calls answered, number of smokers who re-engage in treatment and satisfaction with IVR calls. Hypothesis 2.1 - It is hypothesized that the rates of re-engagement into treatment among those receiving the IVR intervention will be higher than smokers not proactively invited to re-engage in quit line services.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Proactive Care; Type: EXPERIMENTAL; Interventions: Behavioral: Proactive Outreach with choice of telephone or in-person smoking cessation services | Intervention Type: BEHAVIORAL; Name: Proactive Outreach with choice of telephone or in-person smoking cessation services; Assigned to Arm(s): Proactive Care
B: Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling delivered by telephone; Assigned to Arm(s): N/A
C: Arm Label: Life Style Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: IVR intervention | Arm Label: Life Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: IVR control | Intervention Type: BEHAVIORAL; Name: IVR intervention; Assigned to Arm(s): Life Style Counseling | Intervention Type: BEHAVIORAL; Name: IVR control; Assigned to Arm(s): Life Counseling
D: Arm Label: Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD); Type: EXPERIMENTAL; Interventions: Other: Fax to Quit (F2Q) | Arm Label: Fax to Quit alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Fax to Quit (F2Q) | Intervention Type: OTHER; Name: Fax to Quit (F2Q); Assigned to Arm(s): Fax to Quit alone, Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures
Brief Summary: This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.


Options:
A: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures
Brief Summary: This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Adherence to Mammography Use in Chinese Women
Brief Summary: This study examined whether a culturally-tailored video has a greater impact on increasing mammography use in Chinese American women and improving barriers to mammography screening compared to a generic, non-tailored video and a printed fact sheet (control group).


Options:
A: Intervention Type: BEHAVIORAL; Name: Familial risk assessment and personalized prevention messages; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: Culturally-tailored video; Type: OTHER; Interventions: Behavioral: Culturally-tailored video | Intervention Type: BEHAVIORAL; Name: Culturally-tailored video; Assigned to Arm(s): Culturally-tailored video
D: Arm Label: telephone; Type: EXPERIMENTAL; Interventions: Behavioral: telephone | Arm Label: face-to-face; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: consultation face-to-face | Intervention Type: BEHAVIORAL; Name: telephone; Assigned to Arm(s): telephone | Intervention Type: BEHAVIORAL; Name: consultation face-to-face; Assigned to Arm(s): face-to-face

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short-term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport and Dysport NG) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport NG Following Repeated Treatments of Subjects With Cervical Dystonia
Brief Summary: The purpose of this study is to evaluate how well a new drug called Dysport NG works and how safe it is, when it is used for the treatment of cervical dystonia. Dysport NG will be compared to an approved drug called Dysport.


Options:
A: Arm Label: Dysport; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport
B: N/A
C: Arm Label: Dysport®; Type: ACTIVE_COMPARATOR; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dysport NG; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: Dysport; Type: ACTIVE_COMPARATOR; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport NG | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ultrasound Guided 0.25% Ropivacaine Transversus Abdominis Plane Block in Addition to Intrathecal Morphine and Multimodal Analgesia for the Management of Postoperative Pain Among Women Undergoing Cesarean Delivery.
Brief Summary: This study has been designed to determine if women undergoing cesarean delivery with spinal anesthesia and routine pain management who also have an additional ultrasound guided transversus abdominis plane (TAP)block using ropivacaine have better pain relief and a better quality of recovery than women who don't have the additional TAP block. Maximizing pain relief using ultrasound guided TAP blocks in addition to neuraxial opioids, NSAIDs, and acetaminophen may improve acute pain outcomes, reduce adverse side effects, and potentially reduce chronic pain.


Options:
A: Arm Label: 0.25% Ropivicaine; Type: EXPERIMENTAL; Interventions: Drug: Ropivicaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ropivicaine; Assigned to Arm(s): 0.25% Ropivicaine
B: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ultrasound Guided 0.25% Ropivacaine Transversus Abdominis Plane Block in Addition to Intrathecal Morphine and Multimodal Analgesia for the Management of Postoperative Pain Among Women Undergoing Cesarean Delivery.
Brief Summary: This study has been designed to determine if women undergoing cesarean delivery with spinal anesthesia and routine pain management who also have an additional ultrasound guided transversus abdominis plane (TAP)block using ropivacaine have better pain relief and a better quality of recovery than women who don't have the additional TAP block. Maximizing pain relief using ultrasound guided TAP blocks in addition to neuraxial opioids, NSAIDs, and acetaminophen may improve acute pain outcomes, reduce adverse side effects, and potentially reduce chronic pain.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2
B: Arm Label: 0.25% Ropivicaine; Type: EXPERIMENTAL; Interventions: Drug: Ropivicaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ropivicaine; Assigned to Arm(s): 0.25% Ropivicaine
C: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Total Knee Arthroplasty
Brief Summary: The objective of this study is to assess the efficacy of Adductor-Canal-Blockade on pain and morphine consumption after total knee arthroplasty. Our hypothesis is that the Adductor -Canal-Blockade is superior to placebo in reducing pain and morphine consumption after total knee arthroplasty.


Options:
A: Arm Label: proximal catheter insertion; Type: ACTIVE_COMPARATOR; Interventions: Drug: ropivacaine 0.2% | Arm Label: distal catheter insertion; Type: EXPERIMENTAL; Interventions: Drug: ropivacaine 0.2% | Intervention Type: DRUG; Name: ropivacaine 0.2%; Assigned to Arm(s): distal catheter insertion, proximal catheter insertion
B: Arm Label: Adductor-Canal-Block, Ropivacain; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Block, Ropivacain | Arm Label: Adductor-Canal-Block (ACB) - Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Adductor Canal Block, Placebo (saline) | Intervention Type: PROCEDURE; Name: Adductor-Canal-Block, Ropivacain; Assigned to Arm(s): Adductor-Canal-Block, Ropivacain | Intervention Type: PROCEDURE; Name: Adductor Canal Block, Placebo (saline); Assigned to Arm(s): Adductor-Canal-Block (ACB) - Saline
C: Arm Label: Saline boluses in nerve catheter; Type: SHAM_COMPARATOR; Interventions: Procedure: Saline boluses in nerve catheter | Arm Label: Continuous saphenous nerve block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: continuous saphenous nerve block | Intervention Type: PROCEDURE; Name: continuous saphenous nerve block; Assigned to Arm(s): Continuous saphenous nerve block | Intervention Type: PROCEDURE; Name: Saline boluses in nerve catheter; Assigned to Arm(s): Saline boluses in nerve catheter
D: Arm Label: Adductor-Canal-Blockade with Ropivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adductor-Canal-Blockade with Ropivacaine | Arm Label: Adductor-Canal-blockade with saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Adductor-Canal-blockade with saline | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade with Ropivacaine; Assigned to Arm(s): Adductor-Canal-Blockade with Ropivacaine | Intervention Type: PROCEDURE; Name: Adductor-Canal-blockade with saline; Assigned to Arm(s): Adductor-Canal-blockade with saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Education Regarding Living Donor Transplant Among Kidney Transplant Candidates
Brief Summary: The primary purpose of this study is to test different methods by which kidney transplant centers can educate potential transplant candidates about living donor kidney transplant (LDKT).

The most effective ways to educate kidney transplant candidates about LDKT remain unclear. The goal is to determine, among a diverse cohort of potential kidney transplant candidates, whether a transplant center-based intervention will increase understanding of the opportunities for and process, risks, and benefits of living kidney donation and LDKT. The investigators hypothesize that kidney transplant candidates' understanding of living kidney donation and LDKT will be increased by interventions implemented at the transplant center on the day of transplant evaluation.

The investigators propose a single-center, 2-arm, cluster-randomized, controlled trial to compare the effects of two educational strategies upon transplant candidates' understanding of living kidney donation and LDKT:

1. Usual transplant education implemented by the transplant center, on the day of the transplant evaluation (standard care); and
2. Intensive initial transplant education implemented on the day of the transplant evaluation.

Intensive initial transplant education will utilize videos of living donors' experiences as well as a session with a trained Transplant Educator, who will focus upon living donation education. One week after the transplant evaluation day and 3 months later, the investigators will assess transplant candidates' knowledge of LDKT (using questionnaires), identify correlates of increased understanding of LDKT, and assess racial/ethnic differences in the understanding of LDKT.


Options:
A: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A
B: Arm Label: Usual education (standard care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intensive initial education; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive initial education | Intervention Type: BEHAVIORAL; Name: Intensive initial education; Assigned to Arm(s): Intensive initial education
C: Arm Label: A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support for Increased Physical Activity | Intervention Type: BEHAVIORAL; Name: Support for Increased Physical Activity; Assigned to Arm(s): B
D: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention

Answer: B